Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of AL2846 + TQB2450 versus docetaxel in advanced non-small cell lung cancer after immunotherapy failure
CTR20231281Phase 3Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vilzemetkib, benmelstobart, docetaxel in non-small cell lung cancer (NSCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jun 2023; status: active.
02
Drugs
vilzemetkibbenmelstobartdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20231281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231281.